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Abstract
The oncogenic MUC1-C subunit is aberrantly overexpressed in most human breast cancers by 
mechanisms that are not well understood. The present studies demonstrate that stimulation of non-
malignant MCF-10A cells with epidermal growth factor (EGF) or heregulin (HRG) results in 
marked upregulation of MUC1-C translation. Growth factor-induced MUC1-C translation was 
found to be mediated by PI3K->AKT, and not MEK->ERK1/2, signaling. We also show that 
activation of the mTORC1->S6K1 pathway decreases PDCD4, an inhibitor of the eIF4A RNA 
helicase, and contributes to the induction of MUC1-C translation. In concert with these results, 
treatment of growth factor-stimulated MCF-10A cells with the eIF4A RNA helicase inhibitors, 
silvestrol and CR-1-31-B, blocked increases in MUC1-C abundance. The functional significance 
of the increase in MUC1-C translation is supported by the demonstration that MUC1-C, in turn, 
forms complexes with EGFR and promotes EGFR-mediated activation of the PI3K->AKT 
pathway and the induction of growth. Compared to MCF-10A cells, constitutive overexpression of 
MUC1-C in breast cancer cells was unaffected by EGF stimulation, but was blocked by inhibiting 
PI3K->AKT signaling. The overexpression of MUC1-C in breast cancer cells was also inhibited 
by blocking eIF4A RNA helicase activity with silvestrol and CR-1-31-B. These findings indicate 
that EGF-induced MUC1-C expression is mediated by the PI3K->AKT pathway and the eIF4A 
RNA helicase, and that this response promotes EGFR signaling in an autoinductive loop. The 
findings also indicate that targeting the eIF4A RNA helicase is a novel approach for blocking 
MUC1-C overexpression in breast cancer cells.
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Introduction
Protein synthesis is a tightly regulated process that is limited by translation initiation, a step 
controlled by the eIF4F complex at the level of ribosomal recruitment (1). The eIF4F 
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complex is formed by binding of eIF4E to the 5′ cap structure of mRNAs and thereby 
recruitment of eIF4G and eIF4A. Overexpression of eIF4E has been documented in diverse 
human cancers and linked to transformation (2). eIF4E contributes to the malignant 
phenotype by selectively promoting the translation of certain oncoproteins, such as cyclin 
D1, MYC and MCL1, that are involved in growth and survival (2; 3). The PI3K->AKT 
pathway is a major regulator of protein synthesis that is upstream to the mammalian target of 
rapamycin complex 1 (mTORC1) (4). mTORC1 regulates eIF4E activity by phosphorylation 
and thereby inactivation of the inhibitory eIF4E binding proteins (4E-BPs). mTORC1 also 
contributes to cap-dependent translation by activating 40S ribosomal protein S6 kinases 
(S6Ks) that, in turn, enhance the eIF4A RNA helicase activity (1). S6K induces degradation 
of the tumor suppressor programmed cell death protein 4 (PDCD4), which is an eIF4A 
inhibitor (5). eIF4A initiates translation by unwinding highly structured 5′ untranslated 
regions (UTRs) in mRNAs, such as those encoding cyclin D1 and MYC (6). In this way, 
cancer cells can modulate translation in response to growth signals through mTORC1-
induced (i) binding of eIF4E to the 5′ cap structure and (ii) activation of the eIF4A RNA 
helicase function. Dysregulation of translation in malignant cells has supported the 
development of agents that target eIF4E (7) and eIF4A (8; 9). For example, the natural 
product silvestrol is a potent inhibitor of the eIF4A RNA helicase function that blocks cap-
dependent translation and decreases production of cyclin D1, MYC and MCL1 (9; 10). 
Silvestrol has also been shown to be active against cancer cells growing in vitro and in 
animal models (9; 8; 10). These findings have indicated that constitutive activation of PI3K-
>AKT->mTORC1 signaling in cancer cells can be blocked in part by targeting downstream 
effectors of translation.
Mucin 1 (MUC1) is an oncoprotein that is aberrantly overexpressed in human cancers by 
mechanisms that are not clearly understood (11). MUC1 consists of two subunits that form a 
non-covalent complex at the cell membrane (11). The MUC1 N-terminal (MUC1-N) 
ectodomain is the mucin component of the heterodimer that contains glycosylated tandem 
repeats. The transmembrane MUC1 C-terminal subunit (MUC1-C) has a 58 amino acid (aa) 
extracellular domain that interacts with the epidermal growth factor receptor (EGFR) and 
other receptor tyrosines (12; 11). Overexpression of MUC1 in transgenic mouse models is 
associated with binding to EGFR in mammary glands and the induction of breast tumors 
(13; 14). The interaction between MUC1 and EGFR increases EGFR internalization and 
recycling at the cell membrane (15). Other studies have shown that MUC1-C contributes to 
EGFR-mediated activation of the PI3K->AKT pathway (16). In this context, the 72 aa 
MUC1-C cytoplasmic domain binds to PI3K and contributes to activation of the PI3K-
>AKT pathway (17; 16). Overexpression of the MUC1-C subunit, as found in diverse 
human cancers, is sufficient to induce anchorage-independent growth and tumorigenicity 
(18; 19; 11). Upregulation of MUC1-C also attenuates the induction of cell death in response 
to genotoxic, oxidative and hypoxic stress (20–22). MUC1-C localizes to the nucleus, where 
it associates with transcription factors, such as NF-κB RelA and STAT3, and promotes 
activation of their target genes, including MUC1 itself (23; 24). Thus, MUC1-C contributes, 
at least in part, to its own overexpression through autoinductive regulatory loops (11). Based 
on these findings, MUC1-C has emerged as an attractive target for cancer treatment using 
approaches that block its function and thereby overexpression. For example, cell-penetrating 
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peptides and small molecules that inhibit the MUC1-C cytoplasmic domain attenuate 
localization of MUC1-C to the nucleus of cancer cells and downregulate its overexpression 
(25–27). There is, however, no available information about whether MUC1-C can be 
targeted in cancer cells by blocking its expression at the level of translation.
The present results demonstrate that growth factor stimulation of non-malignant MCF-10A 
breast epithelial cells is associated with activation of the PI3K->AKT->mTORC1 pathway 
and thereby induction of MUC1-C translation. In concert with involvement of the eIF4A 
RNA helicase, growth factor-induced MUC1-C translation in MCF-10A cells was inhibited 
by silvestrol and another eIF4A inhibitor, designated CR-1-31-B. The results also show that 
treatment of human breast cancer cells with eIF4A inhibitors is associated with 
downregulation of MUC1-C expression.
Results
Growth factor stimulation induces MUC1-C expression
Abundance of the ~25 kDa MUC1-C protein is relatively lower in non-malignant MCF-10A 
breast epithelial cells as compared to that MCF-7, BT-549 and MDA-MB-468 breast cancer 
cells (Fig. 1A). Consequently, we reasoned that MCF-10A cells might represent a potential 
model to study mechanisms responsible for the overexpression of MUC1-C in breast cancer 
cells. In this context, we found that stimulation of MCF-10A cells with EGF is associated 
with marked upregulation of MUC1-C expression with an increase of over 50-fold at 24 h 
compared to baseline levels (Fig. 1B, left). Densitometric scanning of the signals from 
repetitive experiments further demonstrated a time-dependent increase in MUC1-C 
abundance (Fig. 1B, right). Treatment of MCF-10A cells with heregulin (HRG) was 
similarly associated with a substantial increase in MUC1-C abundance (~50-fold at 24 h 
compared to baseline) (Figs. 1C, left and right). By contrast, EGF had no apparent effect on 
MUC1-C levels in MCF-7 breast cancer cells (Fig. 1D). Stimulation of MCF-7 cells with 
HRG also had no effect on MUC1-C abundance (data not shown), indicating that MUC1-C 
expression is inducible by growth factors in MCF-10A, but not MCF-7, cells.
MUC1-C translation is induced by the PI3K->AKT->mTOR pathway
To define the basis for growth factor-induced increases in MUC1-C expression, we asked if 
the upregulation in levels is mediated by transcriptional and/or post-transcriptional 
mechanisms. EGF stimulation of MCF-10A cells had no significant effect on activation of 
the MUC1 gene promoter in MCF-10A cells (Fig. 2A). Moreover, EGF had no apparent 
effect on MUC1 mRNA levels as determined by qRT-PCR, indicating that the increase in 
MUC1-C protein is regulated at the post-transcriptional level (Fig. 2B). As a control, 
inhibition of protein synthesis with cycloheximide (CHX) blocked EGF-induced increases in 
MUC1-C abundance (Figs. 2C, left and right), confirming that translation of MUC1-C is 
upregulated in the response to growth factor stimulation. Of note, the basal levels of MUC1-
C in MCF-10A cells varies among experiments as a result of differences in exposure times 
used for detection of the signals. Certain signaling pathways, such as MEK->ERK1/2 and 
PI3K->AKT, have been linked to the activation of protein translation (1). To assess potential 
involvement of ERK1/2 and/or PI3K in the regulation of MUC1-C translation, EGF-
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stimulated MCF-10A cells were treated with the dual ERK1/2 inhibitor, U0126 (28), or the 
PI3K inhibitor, LY294002 (29). Inhibition of PI3K, but not ERK1/2, blocked EGF-mediated 
induction of MUC1-C expression (Figs. 2D, left and right).
To extend this analysis, experiments were performed with BEZ235, an inhibitor of PI3K and 
mTOR (30). As found with LY294002, BEZ235 blocked EGF-induced increases in MUC1-
C abundance (Figs. 3A, left and right). In concert with these results, treatment of EGF-
stimulated MCF-10A cells with rapamycin, an allosteric inhibitor of mTOR (1), was also 
associated with a block in the induction of MUC1-C expression (Figs. 3B, left and right). 
mTOR is part of the mTORC1 complex, which phosphorylates the ribosomal protein S6 
kinase 1 (S6K1) and thereby contributes to the initiation of translation (1). The 
demonstration that silencing S6K1 (Fig. 3C) inhibits EGF-induced upregulation of MUC1-C 
levels (Figs. 3D, left and right) provided further support for involvement of the PI3K-
>AKT->mTORC1->S6K1 pathway in the activation of MUC1-C translation.
Inhibiting cap-dependent translation blocks growth factor-induced increases in MUC1-C 
abundance
S6K1-mediated activation of the eIF4A RNA helicase is essential for unwinding of certain 
5′UTRs and induction of translation (4). To address the potential role of eIF4A, we first 
examined expression of the tumor suppressor programmed cell death protein 4 (PDCD4), 
which inhibits the eIF4A RNA helicase activity (31; 32). Stimulation of MCF-10A cells 
with EGF resulted in downregulation of PDCD4 levels in association with increases in 
MUC1-C abundance (Figs. 4A, left and right). Moreover and in concert with the constitutive 
upregulation of MUC1-C in breast cancer cells, PDCD4 was low to undetectable in MCF-7, 
BT-549 and MDA-MB-468 cells (Figs. 4B, left and right). In contrast to PDCD4, there was 
little difference among these cells in terms of eIF4A and eIF4E expression (Fig. 4B, left). 
Whereas PDCD4 inhibits the eIF4A RNA helicase, EGF-stimulated MCF-10A cells were 
treated with silvestrol, an inhibitor of eIF4A RNA helicase activity (8). In this context, there 
is presently no assay for monitoring eIF4A activity in cells and silvestrol is used to assess 
dependence on this helicase (9; 10). Notably, silvestrol blocked EGF-mediated activation of 
MUC1-C translation in a dose-dependent manner (Figs. 4C, left and right). Similar dose-
dependent inhibitory effects were obtained when HRG-stimulated MCF-10A cells were 
treated with silvestrol (Figs. 4D, left and right). MCF-10A cells were also treated with 
silvestrol and monitored for effects on PDCD4 expression. The results demonstrate that 
silvestrol treatment is associated with a marked decrease in PDCD4 abundance (Fig. 4E). 
These findings indicate that (i) growth factor-induced MUC1 translation is associated with 
degradation of PDCD4 and activation of the eIF4A RNA helicase, and (ii) silvestrol blocks 
growth-factor-induced MUC1 translation by inhibiting eIF4A activity. Silvestrol also 
decreased PDCD4 expression in a potential feedback response to the inhibition of eIF4A 
activity.
Upregulation of MUC1-C expression contributes to EGFR-mediated signaling
MUC1-C forms complexes with EGFR at the cell membrane of breast cancer cells (12). 
Coimmunoprecipitation studies were therefore performed to determine whether the 
upregulation of MUC1-C expression affects the formation of EGFR/MUC1-C complexes. 
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Analysis of anti-EGFR precipitates demonstrated a time-dependent increase in the 
association of EGFR and MUC1-C (Fig. 5A). In addition, the increases in EGFR-MUC1-C 
complexes were associated with partial downregulation of EGFR levels observed in the 
response to EGF stimulation (Fig. 5A) (33; 34). These results were extended with confocal 
microscopy studies of EGF-stimulated MCF-10A cells demonstrating increased 
colocalization of EGFR and MUC1-C (Fig. 5B, left). Analysis of the images using Image J 
(35) confirmed a significant increase in EGFR and MUC1-C colocalization after EGF 
stimulation as supported by an enhanced Mander’s overlap coefficient with a NEGFR/
NMUC1-C pixels=1. To further assess the functional role of MUC1-C, we generated 
MCF-10A cells that were stably silenced for MUC1-C expression (Fig. 5C, left). Whereas 
MUC1-C contributes to EGFR-mediated activation of the PI3K->AKT pathway (16), studies 
were performed to assess the effects of MUC1-C silencing on EGF-induced PI3K->AKT 
signaling (Fig. 5C, right). Notably, EGF-induced increases in p-AKT and p-S6K1 were 
suppressed in association with the silencing of MUC1-C (Fig. 5C, right). In concert with 
these results, EGF-induced cell cycle progression was attenuated as a result of MUC1-C 
silencing with increases in G1 phase and decreases in G2 phase (Fig. 5D). In addition, 
decreases in MUC1-C abundance attenuated EGF-stimulated MCF-10A cell growth (Fig. 
5E) and colony formation (Fig. 5F, left and right). These findings indicate that EGF 
stimulates MUC1-C expression and, in turn, MUC1-C promotes EGFR-induced PI3K-
>AKT signaling and cell growth.
eIF4A RNA helicase activity confers translation of MUC1-C in growth factor-stimulated 
MCF-10A cells
To confirm the notion that eIF4A RNA helicase activity induces MUC1-C translation, we 
assessed the effects of a silvestrol analog, designated CR-1-31-B, and its enantiomer 
CR-1-30-B, which is inactive against eIF4A (36) (Fig. 6A). As found with silvestrol, 
CR-1-31-B treatment of EGF-stimulated MCF-10A cells was associated with a dose-
dependent decrease in MUC1-C abundance (Fig. 6B, left). By contrast, the inactive 
CR-1-30-B had no effect on EGF-induced MUC1-C expression (Fig. 6B, right). Treatment 
of MCF-10A cells with CR-1-31-B, but not the inactive CR-1-30-B, also blocked HRG-
induced increases in MUC1-C abundance (Fig. 6C, left and right). In concert with the effects 
of inhibiting the eIF4A RNA helicase on the cap-dependent translation of multiple 
oncoproteins, growth of MCF-10A cells in response to EGF was attenuated by CR-1-31-B 
and not CR-1-30-B (Fig. 6D).
PI3K->AKT pathway and the eIF4A RNA helicase contribute to MUC1-C translation in 
breast cancer cells
Based on the results obtained in MCF-10A cells, we asked if PI3K->AKT-induced 
activation of MUC1-C translation contributes to the constitutive overexpression of MUC1-C 
in breast cancer cells. Accordingly, treatment of MCF-7 cells with LY294002 was 
associated with progressive decreases in MUC1-C abundance that corresponded with 
inhibition of p-AKT (Fig. 7A). In addition, downregulation of MUC1-C protein levels by 
LY294002 occurred in the absence of a detectable effect on MUC1 mRNA levels (data not 
shown). Similar results were obtained with LY294002-treated BT-549 breast cancer cells 
(Fig. 7B), indicating that PI3K->AKT signaling contributes to MUC1-C overexpression. To 
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extend these observations to the regulation of MUC1-C translation, we treated breast cancer 
cells with silvestrol. Exposure of MCF-7 cells to 10 nM silvestrol had a limited effect on 
MUC1-C levels (Fig. 7C). Moreover, treatment with 100 nM silvestrol was associated with 
a more pronounced decrease in MUC1-C abundance (Fig. 7C). Treatment of BT-549 cells 
resulted in a similar dose-dependent effect of silvestrol on MUC1-C levels (Supplemental 
Fig. S1A). Treatment of MDA-MB-468 breast cancer cells also demonstrated decreases in 
MUC1-C that were clearly detectable in response to 10 and 100 nM silvestrol (Fig. 7D). 
Treatment of MCF-7 cells with 100 nM CR-1-31-B was associated with downregulation of 
MUC1-C abundance (Fig. 7E, left). By contrast, the inactive CR-1-30-B enantiomer had no 
apparent effect (Fig. 7E, right). We also found that 100 nM CR-1-31-B, but not the inactive 
CR-1-30-B, decreases MUC1-C expression in BT-549 cells (Supplemental Fig. S1B, left 
and right). In addition, treatment of MDA-MB-468 breast cancer cells with 10 and 100 nM 
CR-1-31-B was associated with decreases in MUC1-C abundance (Fig. 7F). These findings 
collectively indicated that PI3K->AKT signaling activates eIF4A RNA helicase-mediated 
translation of MUC1-C in breast cancer cells.
Discussion
Growth factor-induced PI3K->AKT signaling induces MUC1-C translation
The MUC1 heterodimer is localized at the apical border of normal epithelial cells and is thus 
sequestered from EGFR and other RTKs that reside at the basal-lateral borders (11). In the 
response to stress, epithelial cells lose apical-basal polarity in association with activation of 
a proliferation and survival program (37). Under these circumstances, the MUC1-C subunit 
is now repositioned to form complexes with RTKs, such as EGFR, and promote their 
activation of downstream growth and survival signals (Fig. 8) (11). The present studies 
demonstrate that stimulation of non-malignant MCF-10A mammary epithelial cells with 
EGF results in pronounced increases in MUC1-C translation. Similar effects were observed 
with HRG, an activator of ErbB2, indicating that this increase in MUC1-C levels is not 
restricted to EGFR stimulation. Indeed, our results do not exclude the possibility that 
activation of non-ErbB RTKs similarly induces MUC1-C expression. We also found that 
EGF- and HRG-induced increases in MUC1-C abundance are suppressed by inhibitors of 
the PI3K->AKT pathway and not those that block MEK->ERK1/2 signaling (Fig. 8). AKT 
controls protein synthesis at multiple levels, including ribosome biogenesis, translation 
initiation and elongation, leading to changes in translation of select mRNAs (38). The 
present results demonstrate that like other oncoproteins, for example cyclin D1, MYC and 
MCL1 (4; 1), translation of MUC1-C is selectively induced by growth factor stimulation and 
activation of AKT signaling. The functional significance of upregulating MUC1-C 
translation is supported by the findings that MUC1-C in turn forms complexes with EGFR 
and promotes EGFR-mediated signaling (Fig. 8). In this capacity, previous work has shown 
that EGFR phosphorylates the MUC1-C cytoplasmic domain and that this domain binds to 
PI3K and contributes to the activation of PI3K->AKT signaling (Fig. 8) (39; 17; 12; 16). 
Accordingly, MUC1-C silencing in EGF-stimulated MCF-10A cells attenuated activation of 
AKT and the induction of a proliferative response. These findings support a model in which 
EGF-induced MUC1-C rtranslation activates an autoinductive loop in which MUC1-C in 
turn contributes to EGFR signaling (Fig. 8).
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MUC1-C translation is induced by the eIF4A RNA helicase
AKT controls translation in part through the activation of mTORC1, which results in the 
phosphorylation of several substrates, including S6K (Fig. 8) (4). In turn, S6K 
phosphorylates and thereby induces the degradation of PDCD4, an inhibitor of eIF4A RNA 
helicase activity that regulates translation of proteins, such as p53, that are involved in 
growth and survival (Fig. 8) (5; 40). S6K also phosphorylates eIF4B, which interacts with 
eIF4A and contributes to eIF4A activation (41). In our studies with MCF-10A cells, EGF-
induced increases in MUC1-C translation were blocked by silencing S6K1. Moreover, EGF 
stimulation was associated with downregulation of PDCD4, suggesting that the induction of 
MUC1-C translation could be mediated by the eIF4A RNA helicase. To directly address this 
possibility, we found that EGF-and HRG-induced MUC1-C translation is substantially 
blocked by silvestrol, a natural product isolated from the plant Aglaia silvestris (42). 
Silvestrol inhibits eIF4A by inducing dimerization of eIF4A and RNA (8) and preferentially 
blocks the translation of mRNAs with highly structured 5′UTRs that require efficient 
unwinding by the eIF4F complex (43). In that sense, translation of specific mRNAs varies 
substantially for different transcripts and is dependent in part on the presence of discrete 
hairpin structures in the 5′UTR (2). Notably, the MUC1 5′UTR includes such discrete 
hairpin structures, consistent with a potential requirement for unwinding by the eIF4A RNA 
helicase for translation initiation (Supplementary Fig. S2). In concert with this model, 
silvestrol blocked growth factor-induced MUC1-C translation, but had little effect on the 
abundance of β-actin, which is encoded by a mRNA with a relatively unstructured 5′UTR 
(2). To confirm these results, we showed that CR-1-31-B, a novel inhibitor of the eIF4A 
RNA helicase (36), similarly blocks MUC1-C translation in response to growth factor 
stimulation. By contrast and as a control for specificity, an inactive enantiomer of CR-1-31-
B, designated CR-1-30-B, had no apparent effect on the induction of MUC1-C translation. 
These findings indicate that, like certain other oncoproteins (2), the translation of MUC1-C 
is preferentially induced by growth factor stimulation and activation of the eIF4A RNA 
helicase (Fig. 8).
Targeting cap-dependent translation to block overexpression of MUC1-C in human 
cancers
Dysregulation of protein synthesis has been linked to the development and progression of 
cancers as a result of aberrant cell signaling pathways that converge on translation initiation 
(7). For that reason, drugs have been developed to inhibit mRNA translation by blocking 
eIF4E, eIF4A and other targets that are components of the translational machinery (7). 
MUC1-C is aberrantly overexpressed in breast and other human cancers, and thereby 
contributes to growth and survival pathways (11). Thus, MUC1-C has become an attractive 
target for the treatment of cancers that overexpress this oncogenic subunit (11). The present 
results indicate that targeting MUC1-C translation represents a potential approach to inhibit 
the effects of MUC1-C overexpression in cancer cells. In the breast cancer cells studied in 
the present work, eIF4A and eIF4E levels were similar to those found in non-malignant 
MCF-10A cells. Notably, however, PDCD4 expression was decreased compared to that in 
MCF-10A cells, suggesting that the eIF4A RNA helicase could be of importance to the 
increased levels of MUC1-C in breast cancer cells. In concert with the findings in growth 
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factor-stimulated MCF-10A cells, treatment of breast cancer cells with silvestrol was 
associated with decreases in MUC1-C abundance. Treatment with CR-1-31-B, but not 
CR-1-30-B, similarly resulted in downregulation of MUC1-C levels, indicating that the 
eIF4A RNA helicase activity is responsible, at least in part, for overexpression of MUC1-C 
in these cells (Fig. 8). CR-1-31-B was also effective in inhibiting breast cancer cell growth, 
consistent with the downregulation of diverse oncoproteins that are dependent on the eIF4A 
RNA helicase for translation (Supplemental Fig. S3). Cell-penetrating peptide and small 
molecule inhibitors have been developed that directly block the MUC1-C oncogenic 
function and induce death of breast cancer cells (25; 27). Targeting MUC1-C translation to 
decrease MUC1-C abundance could thus conceivably increase the effectiveness of these 
direct inhibitors. Finally, agents such as silvestrol and CR-1-31-B, are likely to be highly 
effective as anti-cancer agents given that, in addition to MUC1-C, multiple oncoproteins, 
including cyclin D1, MYC and MCL1, are downregulated by inhibiting the eIF4A RNA 
helicase. Indeed, preclinical studies with silvestrol in animal models have demonstrated 
promising anti-tumor activity with little toxicity, supporting the selectivity of blocking 
eIF4A function for cancer treatment (8–10).
Materials and Methods
Cell culture
Human MCF-10A mammary epithelial cells were grown in mammary epithelial growth 
medium (MEGM, Lonza). Human MCF-7 and MDA-MB-468 breast cancer cells were 
cultured in Dulbecco’s modified Eagle’s medium with 10% heat-inactivated fetal bovine 
serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine. Human 
BT-549 cells were maintained in RPMI-1640 medium (ATCC) with 10% FBS and 0.023 
IU/ml insulin. Cells were treated with EGF (Sigma), heregulin beta 1 (HRG; Neomarkers), 
cycloheximide (CHX, Calbiochem), U0126 (Calbiochem), LY294002 (Caymam Chemical 
Company), BEZ-235 (Selleckchem) and rapamycin (Cell Signaling Technology). In certain 
experiments, MCF-10A cells were serum-starved overnight, and inhibitors were added 2.5 h 
prior to EGF or HRG treatment.
eIF4A inhibitors
Silvestrol (44), CR-1-31-B (36), and its enantiomer CR-1-30-B (36) were synthesized 
according to literature procedures.
Immunoblot analysis
Lysates from subconfluent cells were immunoblotted with anti-MUC1-C (Ab5; 
Neomarkers), anti-β-actin (Sigma), anti-p-AKT, anti-AKT, anti-p-ERK1/2, anti-ERK1/2, 
anti-p-S6K1, anti-S6K1, anti-PCDC4, anti-eIF4E, eIF4A (Cell Signaling Technology) and 
anti-EGFR (Santa Cruz Technology). Immune complexes were detected with horseradish 
peroxidase-conjugated secondary antibodies and enhanced chemiluminescence (Amersham 
Biosciences). Intensity of certain signals was determined by densitometric scanning. 
Statistical significance was determined by the Student’s t-test.
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Luciferase assays
Control pGL3 or pGL3-MUC1-promoter constructs were transfected with the Renilla 
plasmid into cells in the presence of Lipofectamine. At 24 h after transfection, cells were 
serum-starved overnight, and then treated with EGF (100 ng/ml) for 5 h. Luciferase reporter 
activity was measured using the Promega Dual Glo kit.
Real-Time PCR
Total RNA was isolated from cells using an RNeasy Mini kit (Qiagen). cDNAs were 
synthesized with 0.3–1 μg RNA using the first-strand cDNA synthesis kit (Invitrogen). The 
SYBR green qPCR assay kit (Applied Biosystems) was used with 5 μl of 20-fold diluted 
cDNA from each sample, and the samples were amplified with the ABI Prism 7300 machine 
(Applied Biosystems).
Coimmunoprecipitation experiments
MCF-10A cells were treated with EGF and lysed for 30 min on ice. Cell lysates were 
incubated with control IgG or anti-EGFR overnight at 4°C with agitation. Protein G-
Sepharose beads (GE Health Care Life Sciences) were added and the cell lysates were 
incubated for another 2 h. Immune complexes were collected, washed in lysis buffer and 
subjected to immunoblotting with anti-MUC1-C and anti-EGFR.
Confocal microscopy
MCF-10A cells were seeded onto a 6-well plate with sterile cover slides. After overnight 
serum starvation, cells were treated with EGF for 24 h. Cells were fixed in 100% acetone, 
blocked with 5% milk in PBS and stained with an anti-EGFR monoclonal antibody (Santa 
Cruz Biotechnology), anti-MUC1-C (Neomarkers) and Hoechst 33258 (Invitrogen). The 
cover slides were mounted onto microscope slides using Prolong Gold antifade reagent 
(Invitrogen) and imaged by confocal microscopy.
Assessment of cell cycle distribution
Cells were fixed in ice-cold 100% ethanol overnight, washed with PBS, incubated with 100 
μg/ml RNase for 30 min at 37°C, stained with 10 μg/ml propidium iodide at room 
temperature for 30 min, and analyzed by flow cytometry.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
MUC1 mucin 1
MUC1-C MUC1 C-terminal subunit
MUC1-CD MUC1 cytoplasmic domain
EGF epidermal growth factor
HRG heregulin
mTORC1 mammalian target of rapamycin complex 1
S6K1 ribosomal protein S6 kinase 1
CHX cycloheximide
PDCD4 tumor suppressor programmed cell death protein 4
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Figure 1. Stimulation of non-malignant MCF-10A breast epithelial cells with EGF or HRG 
induces MUC1 expression
A. Lysates from MCF-10A cells and the indicated breast cancer cells were immunoblotted 
with anti-MUC1-C and anti-β-actin. B. MCF-10A cells were stimulated with 100 ng/ml EGF 
for the indicated times. Lysates were immunoblotted with anti-MUC1-C and anti-β-actin 
(left). Intensity of the MUC1-C signals was determined by densitometric scanning. The 
results (mean±SD of three replicates) are expressed as relative MUC1-C levels compared to 
that obtained for the untreated control (assigned a value of 1) (right). C. MCF-10A cells 
were stimulated with 10 ng/ml HRG for the indicated times. Lysates were immunoblotted 
with the indicated antbodies (left). The results (mean±SD of three replicates) are expressed 
as relative MUC1-C levels compared to that obtained for the untreated control (assigned a 
value of 1) (right). D. MCF-7 cells were stimulated 100 ng/ml EGF for the indicated times. 
Lysates were immunoblotted with the indicated antibodies.
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Figure 2. Activation of the PI3K pathway induces MUC1-C translation
A. MCF-10A cells were transfected with the control pGL3 (CTL) or pMUC1-Luc in the 
presence of Renilla plasmid for 24 h. The cells were then stimulated with EGF for 5 h and 
then assayed for luciferase activity. The results are expressed as the fold-activation (mean
±SD of three determinations) relative to that obtained for the pGL3 plasmid. B. MCF-10A 
cells were stimulated with EGF for the indicated times. MUC1 mRNA levels (mean±SD of 
three determinations) were assayed by qRT-PCR. C. MCF-10A cells were stimulated with 
EGF in the absence and presence of 10 ng/ml CHX for the indicated times. Lysates were 
immunoblotted with anti-MUC1-C and anti-β-actin (left). The results (mean±SD of three 
replicates) are expressed as relative MUC1-C levels compared to that obtained for the 
untreated control (assigned a value of 1) (right). D. MCF-10A cells were stimulated with 
EGF in the presence of 10 μM U0126 or 50 μM LY294002 for 8 and 24 h. Lysates were 
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immunoblotted with the indicated antibodies (left). The results (mean±SD of three 
replicates) are expressed as relative MUC1-C levels compared to that obtained for the 
untreated control (assigned a value of 1) (right).
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Figure 3. MUC1-C translation is induced by PI3K->mTOR->S6K1 signaling
A. MCF-10A cells were stimulated with EGF in the presence of 250 or 500 nM BEZ235 for 
the indicated times. Lysates were immunoblotted with the indicated antibodies (left). The 
results (mean±SD of three replicates) are expressed as relative MUC1-C levels compared to 
that obtained for the untreated control (assigned a value of 1) (right). B. MCF-10A cells 
were stimulated with EGF in the presence of 100 nM rapamycin for the indicated times. 
Lysates were immunoblotted with anti-MUC1-C and anti-β-actin (left). The results (mean
±SD of three replicates) are expressed as relative MUC1-C levels compared to that obtained 
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for the untreated control (assigned a value of 1) (right). C. MCF-10A cells were transfected 
to express a control siRNA or a S6K1 siRNA pool. Lysates from the transfected cells were 
immunoblotted with the indicated antibodies. D. MCF-10A cells transfected with the 
CsiRNA or S6K1siRNA were left untreated (CTL) or stimulated with EGF for 24 h. Lysates 
were immunoblotted with the indicated antibodies (left). The results (mean±SD of three 
replicates) are expressed as relative MUC1-C levels compared to that obtained for the 
control (assigned a value of 1) (right).
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Figure 4. Growth factor-induced MUC1-C expression is regulated by cap-dependent translation
A. MCF-10A cells were stimulated with EGF for 8 and 24 h. Lysates were immunoblotted 
with the indicated antibodies (left). The results (mean±SD of three replicates) are expressed 
as relative PDCD4 levels compared to that obtained for the untreated control (assigned a 
value of 1) (right). B. Lysates from MCF-10A, MCF-7, BT-549 and MDA-MB-468 cells 
were immunoblotted with the indicated antibodies (left). The results (mean±SD of three 
replicates) are expressed as relative PDCD4 levels compared to that obtained for MCF-10A 
cells (assigned a value of 1) (right). C and D. MCF-10A cells were left untreated (CTL) and 
stimulated with EGF (C) or HRG (D) in the presence of the indicated concentrations of 
silvestrol for 24 h. Lysates were immunoblotted with anti-MUC1-C and anti-β-actin (left). 
The results (mean±SD of three replicates) are expressed as relative MUC1-C levels 
compared to that obtained for the control (assigned a value of 1) (right). E. MCF-10A cells 
were treated with 100 nM silvestrol for the indicated times. Lysates were immunoblotted 
with anti-PDCD4 and anti-β-actin.
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Figure 5. MUC1-C contributes to EGFR-mediated signaling and cell growth
A. MCF-10A cells were stimulated with EGF for the indicated times. Lysates were 
precipitated with a control IgG or anti-EGFR. The precipitates were immunoblotted with 
anti-MUC1-C or anti-EGFR. B. MCF-10A cells were left untreated (CTL) or stimulated 
with EGF for 24 h. Cells were stained with anti-MUC1-C and anti-EGFR, and analyzed by 
confocal microscopy (left). The images were analyzed by Image J (35) to confirm increased 
colocalization of EGFR and MUC1-C in the response to EGF stimulation (right). C. Lysates 
from MCF-10A cells stably transfected to express a control siRNA or a MUC1 siRNA were 
immunoblotted with the indicated antibodies (left). The MCF-10A/CsiRNA and MCF-10A/
MUC1siRNA cells were left untreated or stimulated with EGF for 24 h (right). Lysates were 
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immunblotted with the indicated antibodies. D. MCF-10A/CsiRNA and MCF-10A/
MUC1siRNA cells were stimulated with EGF for 24 h. Control (CTL) and EGF-treated cells 
were stained with PI and analyzed for cell cycle distribution by flow cytometry. The 
percentage of cells in G1, S and G2 phase are included in the panels. E. MCF-10A/CsiRNA 
and MCF-10A/MUC1siRNA cells were stimulated with EGF for 24 h, reseeded and then 
counted at 48 h. The results are expressed as cell number (mean±SD of three 
determinations). F. MCF-10A/CsiRNA and MCF-10A/MUC1siRNA cells were stimulated 
with EGF for 24 h and reseeded into 6-well plates (1000 cells per well). Colonies were 
stained with crystal violet, photographed (left) and counted (right) on day 7. The results are 
expressed as colony number (mean±SD of three determinations) (right).
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Figure 6. MUC1-C translation is inhibited by CR-1-31-B in MCF-10A cells
A. Structures of the indicated compounds. B and C. MCF-10A cells were left untreated 
(CTL) and stimulated with EGF (B) or HRG (C) in the presence of the indicated 
concentrations of CR-1-31-B (left) or inactive CR-1-30-B (right) for 24 h. D. MCF-10A 
cells were stimulated with EGF in the absence (CTL) or presence of 100 nM CR-1-31-B or 
CR-1-30-B for 24 h, reseeded and then counted at 48 h. Viable cell number (mean±SD of 
three determinations) was determined by trypan blue exclusion.
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Figure 7. MUC1-C translation is regulated by PI3K->AKT signaling and eIF4A in breast cancer 
cells
A and B. MCF-7 (A) and BT-549 (B) cells were treated with LY294002 for the indicated 
times. Lysates were immunoblotted with the indicated antibodies. C–D. MCF-7 (C) and 
MDA-MB-468 (D) cells were treated with 10 or 100 nM silvestrol for the indicated times. 
Lysates were immunoblotted with anti-MUC1-C and anti-β-actin. E and F. MCF-7 (E) and 
MDA-MB-468 (F) cells were treated with 100 nM CR-1-31-B or inactive CR-1-30-B for the 
indicated times. Lysates were immunoblotted with anti-MUC1-C and anti-β-actin.
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Figure 8. Proposed autoinductive loop in which MUC1-C contributes to activation of the EGFR-
>PI3K->AKT->mTOR pathway and thereby increased translation of the MUC1-C protein
MUC1-C forms complexes with EGFR at the cell membrane that are mediated by 
extracellular galectin-3 bridges. Stimulation of EGFR with EGF induces phosphorylation of 
the MUC1-C cytoplasmic domain, promotes binding of the PI3K SH2 domains and thereby 
activation of the PI3K->AKT->mTOR pathway. mTOR-mediated phosphorylation and 
activation of S6K1 induces degradation of PDCD4, an inhibitor of the eIF4A RNA helicase. 
Derepression of eIF4A activity stimulates MUC1-C translation with marked increases in 
MUC1-C protein and, in turn, the formation of EGFR/MUC1-C complexes. This 
autoinductive loop is constitutively activated in breast cancer cells and disrupted by the 
eIF4A inhibitors, silvestrol and CR-1-31-B.
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